CpG oligonucleotides elicit antitumor responses in a human melanoma NOD/SCID xenotransplantation model.

For patients with advanced malignant melanoma, the 5 y survival rate with current treatment modalities is low. There is an urgent need for more effective therapeutic concepts. One approach with great potential is to stimulate the body's own immune defense to reject cancer cells using CpG oligonucleotides. Distinct oligonucleotides containing nonmethylated… CONTINUE READING